BTIG Research Upgrades Endologix To Buy, Shares Gain

By: via Benzinga
Analysts at BTIG Research upgraded Endologix (NASDAQ: ELGX) from Neutral to Buy. The target price for Endologix is set to $17. ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.